TH — Theratechnologies Share News
0.000.00%
Last trade - 00:00- CA$205.53m
- CA$252.52m
- $85.87m
Brief: Theratechnologies Receives Refusal To File Letter For Trogarzo Intramuscular Method Of Administration sBLA From FDA
Theratechnologies Inc reports results for the quarter ended in November - Earnings Summary
Theratechnologies rises on smaller-than-expected Q4 loss
Theratechnologies down as FDA declines to approve new form of fat reduction drug
Brief: Theratechnologies Says CRL Does Not Impact Commercial Availability Of EGRIFTA SV
US-listed shares of Theratechnologies falls as FDA extends drug review
Brief: Theratechnologies Receives Update From FDA On Tesamorelin F8 Supplemental Biologic License Application
Brief: Theratechnologies Submits SBLA For Trogarzo® INTRAMUSCULAR (IM) METHOD To FDA
Brief: Theratechnologies Inc Files For Mixed Shelf For Up To $100 Mln- SEC Filing
Brief: Theratechnologies Announces FDA Approval Of Trogarzo
Brief: Soleus Capital Master Fund, L.P.- Have Engaged, And Intend To Continue To Engage, In Communications With Theratechnologies Inc Board
Brief: Investissement Québec Reports 19.9% Stake In Theratechnologies Inc As Of October 31 - SEC Filing
Brief: Theratechnologies Announces Pricing Of $25 Million Public Offering Of Common Shares
Brief: Theratechnologies Announces Proposed Public Offering Of Common Shares
Brief: Theratechnologies Says Co To See Tapering of R&D Activites, Cut Up To 25 Positions
Brief: Theratechnologies’ Shares Data Demonstrating Cost-Effectiveness Of Ibalizumab
Brief: Theratechnologies Announces Finalization Of Amendments To Some Of The Terms And Conditions Of Its Credit Agreement With Marathon
Brief: Theratechnologies Announces Results From Trogarzo(Ibalizumab-Uiyk) Intramuscular Administration Study
Brief: Theratechnologies Announces Dosing Of First Patient In Updated Clinical Trial Of Sudocetaxel Zendusortide In Advanced Ovarian Cancer